Biopure Gives Update on Malaysia Joint Venture Discussions

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Biopure Gives Update on Malaysia Joint Venture Discussions
    CAMBRIDGE, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announced today the status of discussions with Malaysia
about a possible joint venture. The possibility of such a venture was
described by a Malaysian government official to the Malaysian national news
agency Bernama in early July.
    As indicated in the July statements in Malaysia, Biopure and officials
representing public and private interests in Malaysia have been in
discussions related to a possible joint venture between the company and a
Malaysian entity under the Malaysian Ministry of Science Technology and
Innovation.
    The Malaysian Ministry has expressed to Biopure its wish to pursue a
Hemopure joint venture licensing agreement for Malaysia and certain other
countries in Asia upon Biopure's receipt of marketing authorization for
Hemopure in the United Kingdom. The investment as discussed, would be well
over $100 million. The following broad terms have been discussed:
    -- A direct investment in Biopure common stock-up to 19.9% of the company.
    -- Licensing rights for Hemopure(R).
    -- The funding by Malaysia of a joint venture company to be owned by
       Biopure and a Malaysian entity.
    -- A large-scale plant for manufacturing Hemopure in Malaysia, at an
       estimated cost in excess of $100 million, with government financing.
    Many details and final agreements must still be reached between Biopure
and Malaysia should the company receive U.K. market approval for Hemopure.
Malaysia has conducted business, medical and regulatory due diligence,
including diligence in the United States and South Africa.
    Biopure continues to believe there is a reasonable chance that Hemopure
can be approved for a surgical patient population when blood is not
available or an option in the United Kingdom. There is no prescribed time
frame for a final decision from the U.K. licensing authority once Biopure
makes its submission addressing pending MHRA questions, but four to six
months is typical. Biopure expects to meet with the MHRA and make its
response in September.
    Biopure Corporation
    Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic.
    Biopure has applied in the United Kingdom for regulatory approval of a
proposed orthopedic surgical anemia indication. The company is developing
Hemopure for a potential indication in cardiovascular ischemia, in addition
to supporting the U.S. Navy's government- funded efforts to develop a
potential out-of-hospital trauma indication. Biopure's veterinary product
Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only
oxygen therapeutic approved by the U.S. Food and Drug Administration and
the European Commission, is indicated for the treatment of anemia in dogs.
Biopure has sold approximately 186,000 units of Oxyglobin, which have been
used to treat an estimated 100,000 animals.
    Statements in this release that are not strictly historical are
forward- looking statements, including those statements regarding possible
future discussion of a transaction with involving Malaysia, the terms of
any such transaction, and that Hemopure may receive marketing approval in
the U.K.. Actual results and their timing may differ materially from those
projected in these forward-looking statements due to risks and
uncertainties. These risks include, without limitation, uncertainties
regarding the company's financial position, unexpected costs and expenses,
delays and adverse determinations by regulatory authorities, the company's
ability to respond to requests for additional data, unanticipated problems
with the product's commercial use, whether or not product related, and
delays in or unpredictable outcomes of clinical trials, and the factors
identified under the heading "Risk Factors" in the company's quarterly
report on Form 10-Q filed on June 14, 2007, which can be accessed in the
EDGAR database at the U.S. Securities and Exchange Commission's (SEC)
website, http://www.sec.gov. The company undertakes no obligation to
release publicly the results of any revisions to these forward- looking
statements to reflect events or circumstances arising after the date
hereof. A full discussion of the company's operations and financial
condition can be found in the company's filings with the SEC.
    The content of this release does not necessarily reflect the position
or the policy of the U.S. Government or the Department of Defense, and no
official endorsement should be inferred.
    Contact:
    Todd Wood
    Biopure Corporation
    (617) 234-6576
    IR@biopure.com

    Herb Lanzet (Investors)
    H.L. Lanzet Inc.
    (212) 888-4570
    lanzet@aol.com
SOURCE Biopure Corporation
http://www.biopure.com/
http://www.prnewswire.com/comp/131224.html /
CONTACT:
Todd Wood of Biopure Corporation,
+1-617-234-6576, IR@biopure.com; or Investors, Herb Lanzet of
H.L. Lanzet Inc., +1-212-888-4570, lanzet@aol.com, for Biopure
Corporation